Supernus Pharmaceuticals

SUPN · NASDAQ

$41.23+$1.39 (+3.49%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $39.84

SUPN analyst rating

BuyConsensus of 4 analysts over the last 12 months. 75% rate it a buy.

Strong buy0
Buy3
Hold1
Underperform0
Sell0

12-month price target · 7 analysts

Average $63.85 (+54.9% upside)

Low: $55.55
Now: $41.23
High: $70.35

Upgrades and downgrades

The latest rating actions, newest first

SUPN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Cantor Fitzgerald	Jul 9, 2026	Maintains	Overweight	$63.00 → $67.00	41%
Stifel	Dec 19, 2025	Maintains	Hold	$50.00 → $55.00	45%
B of A Securities	Oct 29, 2025	Initiates	Buy	$65.00	0%
TD Cowen	Oct 23, 2025	Maintains	Buy	$45.00 → $60.00	17%

The case for and against

Updated Mar 20, 2026

Bull case

Supernus Pharmaceuticals Inc. is experiencing growing interest in its ONAPGO product, a continuous subcutaneous apomorphine infusion for advanced Parkinson's disease, suggesting potential for increased market demand. The company's conservative management approach indicates that once demand is better understood, there may be an adjustment to projected peak sales, fostering a positive outlook for financial performance. Additionally, the anticipation surrounding the upcoming 3Q25 call could reveal further dynamics that enhance the company’s growth prospects.

Bear case

Supernus Pharmaceuticals Inc faces significant risks that contribute to a negative outlook, primarily centered around the company's potential failure in commercial execution, which could hinder its market potential. Additionally, the inherent uncertainty in clinical trial outcomes poses a further threat, as negative results could prevent the approval of new or expanded indications for its products. These factors collectively undermine the company's ability to establish a robust portfolio within a competitive landscape for central nervous system treatments.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.